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In pemphigus vulgaris and pemphigus foliaceus (PF), autoan-
tibodies against desmoglein-3 and desmoglein-1 induce epider-
mal cell detachment (acantholysis) and blistering. Activation of
keratinocyte intracellular signaling pathways is emerging as an
important component of pemphigus IgG-mediated acantholy-
sis.We previously reported activation of p38mitogen-activated
protein kinase (MAPK) in response to pathogenic pemphigus
vulgaris and PF IgG. Inhibition of p38MAPK blocked pemphi-
gus IgG-induced cytoskeletal reorganization in tissue culture
and blistering in pemphigus mouse models. We now extend
these observations by demonstrating two peaks of p38MAPK
activation in pemphigus tissue culture and mouse models.
Administration of the p38MAPK inhibitor SB202190 before PF
IgG injection blocked both peaks of p38MAPKphosphorylation
and blister formation, consistent with our previous findings;
however, administration of the inhibitor 4 h after PF IgG injec-
tion blocked only the later peak of p38MAPK activation but
failed to block blistering. Examination of the temporal relation-
ship of p38MAPK phosphorylation and apoptosis showed that
apoptosis occurs at or after the second peak of p38MAPK acti-
vation. The time course of p38MAPK activation and apoptotic
markers, as well as the ability of inhibitors of p38MAPK to block
activationof theproapoptotic proteinase caspase-3, suggest that
activation of apoptosis is downstream to, and a consequence of,
p38MAPK activation in pemphigus acantholysis. Furthermore,
these observations suggest that the earlier peak of p38MAPK
activation is part of the mechanism leading to acantholysis,
whereas the later peak of p38MAPK and apoptosis may not be
essential for acantholysis.
Pemphigus is a group of related autoimmune diseases char-
acterized by blistering in the skin. The histologic hallmark of
these disorders is termed acantholysis, which describes the loss
of adhesion between adjacent epithelial cells. The two major
variants are pemphigus foliaceus (PF)2 and pemphigus vulgaris
(PV). In PF, acantholysis is observed beneath the stratum cor-
neum and within the granular layer of epidermal epithelia,
whereas in PV, blister formation occurs above the basal layer of
epidermal epithelia andmucosal epithelium. Passive transfer of
IgG purified from both PV and PF patient sera reproduces the
clinical, histological, and immunologic features of the human
diseases, demonstrating that these autoantibodies are patho-
genic (1, 2). In PF, autoantibodies target the desmosomal cad-
herin desmoglein (dsg) 1, whereas in PV, autoantibodies ini-
tially target dsg3 (3, 4) in mucosal PV and then subsequently
target both dsg1 and dsg3 in mucocutaneous PV (5–7).
The mechanism by which pemphigus autoantibodies induce
blistering has been under investigation.Work fromanumber of
laboratories has suggested that activation of intracellular events
is induced by binding of PF or PV IgG to dsg1 and dsg3, respec-
tively (8–14). Previously, we have reported that PV IgG activate
p38MAPK and heat shock protein (HSP) 27 in human kerati-
nocyte tissue cultures (15). Significantly, p38MAPK inhibitors
blocked PV IgG-induced keratin filament retraction and actin
reorganization in human keratinocyte tissue cultures. Further-
more, we have demonstrated that both PV and PF IgG induce
phosphorylation of p38MAPK and HSP25, the murine HSP27
homologue, in mouse models and that inhibitors of p38MAPK
block blistering in both the PV (16) and the PF (17) passive
transfer mouse models. Additionally, in human skin biopsies
from both PV and PF patients, phosphorylation of p38MAPK
and HSP27 has been observed (18). Collectively, these observa-
tions suggest that activation of p38MAPK within the target ke-
ratinocyte contributes directly to loss of cell-cell adhesion
induced by pemphigus autoantibodies.
Both p38MAPK and HSP27 have been implicated in the reg-
ulation of the intermediate filament and actin cytoskeletons
(19–25); the ability of p38MAPK inhibitors to block both pem-
phigus IgG-activated cytoskeletal reorganization and pemphi-
gus IgG-activated blistering suggests that p38MAPK may be
acting upstream of the cytoskeleton in the mechanism of acan-
tholysis; however, p38MAPK signaling has been implicated in
other cellular responses (reviewed in Ref. 26). For example,
there is abundant evidence for p38MAPK involvement in apo-
ptosis (27–29); however, the role of p38MAPK in apoptosis
seems to be cell type- and stimulus-dependent. Although
p38MAPK signaling promotes cell death in some cell lines, it
also functions to enhance survival, growth, and differentiation
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in other cell lines (30). Several reports describe increased apo-
ptosis of keratinocytes in pemphigus (31–35); however, the
relationship between PV IgG-mediated p38MAPK signaling,
the induction of apoptosis, and the relationship of apoptosis to
blistering has not been defined. This study was undertaken to
investigate the relationship betweenp38MAPKactivation, apo-
ptosis, and acantholysis.
EXPERIMENTAL PROCEDURES
Materials—Rabbit polyclonal anti-p38MAPK antibodies
were from Santa Cruz Biotechnology (Santa Cruz, CA), mono-
clonal anti-phospho-p38MAPK antibodies and anti-phospho-
HSP 27 were from Cell Signaling Technology (Beverly, MA),
and rabbit polyclonal anti-HSP25 antibodies were from Stress-
Gen (Victoria, BC, Canada). The p38MAPK inhibitor SB
202190was fromCalbiochem.A rabbitmonoclonal antibody to
cleaved caspase 3, a monoclonal antibody to human cleaved
poly(ADP-ribose) polymerase (PARP), and a polyclonal anti-
body to murine cleaved PARP were from Cell Signaling
Technology.
IgG Preparation—PV IgG and PF IgG were purified form PV
and PF patient sera respectively by ammonium sulfate precipi-
tation followed by affinity chromatography on protein G
(HiTrap; Amersham Biosciences) as described previously (15).
IgG fractions were dialyzed against PBS, sterile filtered, and
purity-confirmed by SDS-PAGE; activity was assayed by indi-
rect IF and enzyme-linked immunosorbent assay. Data from in
vivo passive transfer mouse experiments utilized IgG purified
from a single PF patient whose serumwas available in sufficient
quantities to carry out the described studies. The activity of this
serum was determined by indirect IF on sectioned normal
human skin with a titer of 1: 2560. Dsg3, not dsg1, is the pre-
dominant desmosomal cadherin in primary human keratino-
cyte monolayer tissue cultures; therefore, PV IgG was used for
tissue culture experiments. The activity of this PV IgG was
1:640 by testing with indirect IF on sectioned monkey esopha-
gus. Control IgG, which showed no activity by indirect IF, was
prepared in parallel from normal human sera.
Passive Transfer Mouse Model—Breeding pairs of C57BL/6J
mice were purchased from The Jackson Laboratory (Bar Har-
bor, ME) and maintained at the Division of Laboratory Animal
Medicine Facility of theUniversity ofNorthCarolina in accord-
ance with International Animal Care and Use Committee pro-
tocols. Neonatal mice, 24–36 h old and weighing 1.4–1.6 g,
were used for passive transfer experiments. Neonates were
injected intradermally with a sterile solution of either PF IgG or
control IgG at a dose of 0.1 mg of IgG per gram of body weight
in a total volume of 50 l of PBS as described previously (16).
For time course studies of p38MAPK activation, samples
were collected at 1, 2, 4, 6, 8, and 21 h after injection. For detec-
tion of apoptotic activity, additional time points at 24, 30, 48,
and 50 h were collected. At the specified time point, mice were
examined clinically and sacrificed. Skin biopsies were obtained
at the IgG injection site and divided as follows.One-quarterwas
fixed and stained with hematoxylin/eosin for routine histolog-
ical examination, and one-fourth was rapidly frozen and used
for immunofluorescence staining; the remaining half was uti-
lized for biochemical studies. Protein extracts were prepared
from skin biopsies by glass pestle homogenization in Nonidet
P-40 lysis buffer (1% Nonidet P-40, 150 mM NaCl, 50 mM Tris-
HCl, pH 7.4, 1 mM EDTA, 10 M pepstatin, 100 M leupeptin,
10 M E-64, 1 mM phenylmethylsulfonyl fluoride, 500 M
Na3VO4, 50 mM NaF, 0.5 M okadaic acid).
Keratinocyte Cell Culture—Normal primary human kerati-
nocytes (from Cascade Biologics, Portland, OR) grown in Epil-
ife medium containing 60 M CaCl2 and human keratinocyte
growth supplement were passaged and expanded as described
(15, 36). Third passage keratinocytes were grown to 80–90%
confluence when PV IgG, control IgG, or an equivalent volume
of buffer was added and subsequently incubated for various
times from30min to 10 h in the presence of 0.5mMCaCl2. Cells
were washed three times with ice-cold PBS and were harvested
in isoelectric focusing lysis buffer (10 M pepstatin, 100 M
leupeptin, 10 M E-64, 1 mM phenylmethylsulfonyl fluoride,
500 M Na3VO4, 50 mM NaF, 0.5 M okadaic acid).
Gel Electrophoresis—Samples were equally loaded on and
separated by 10% SDS-PAGE. Gels were transferred to polyvi-
nylidene difluoride (Millipore, Billerica, MA) membranes and
probed by immunoblot for proteins of interest. Western blots
were developed by enhanced chemiluminescence (ECL) reac-
tion (Amersham Biosciences). The signal intensity was quanti-
fied by scanning chemiluminescence on a GeneGnome HR
scanner (Syngene, Frederick, MD) using GeneSnap software.
Immunofluorescence and Confocal Microscopy of Murine
Skin—Frozen sections 7 m in thickness were cut freshly on a
Cryostat and transferred onto gelatin-coated glass slides. The
sections were fixed and permeabilized in 20 °C methanol for
15 min and blocked in 5% normal goat serum for 1 h at room
temperature. After rinsing, sections were incubated overnight
at 4 °C in PBSwith 0.1%Triton-100, 1%normal goat serum, and
one of the following antibodies at the indicated dilutions: 1)
1:200 anti-p38MAPK antibody or 2) 1:100 anti-phospho-
p38MAPK antibody. Primary antibodies were detected by
exposure for 1 h to Cy3-conjugated secondary antibodies (Jack-
son ImmunoResearch Laboratories, West Grove, PA) diluted
1:400. Fluorescence patterns were examined using a Leica
inverted DM IRB microscope and by confocal microscopy
using a Leica SP2AOBS confocalmicroscopewith an excitation
wavelength of 543 nmand capture at 580 nmusing a63 objec-
tive with numerical aperture of 1.4.
Immunofluorescence Microscopy of Human Keratinocytes—
Normal human keratinocytes were grown on 22-mm2 glass
coverslips and then treated with PV IgG, control IgG, or an
equivalent volume of serum-free medium, at 37 °C. Cells were
fixed in 3.7% paraformaldehyde for 5 min at room temperature
and permeabilized in 0.25% Triton X-100 for 10min. Immuno-
fluorescence analysis was performed using the mouse mono-
clonal anti-cleaved PARP antibodies at a 1:800 dilution fol-
lowed by Cy3-conjugated secondary antibodies at a dilution of
1:200. Actin was stained with Alexa Fluor 488 phalloidin
(Invitrogen) at a dilution of 1:60. After the final wash, the cov-
erslips weremounted on slides with ProLong gold antifade rea-
gent with 4,6-diamidino-2-phenylindole (Invitrogen). For a
positive control, cells were treated for 3 h with 0.3 M stauros-
porine to induce apoptosis; the negative control consisted of
omitting the primary antibodies. Images were obtained on a
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Leica DM IRB invertedmicroscope with a high sensitivity CCD
camera and PCI imaging software (Version 6.5, Hamamatsu
Corp., Sewickley, PA).
In a second set of experiments, primary human keratinocytes
were grown on glass coverslips and either (i) pretreated with
DMSO as a vehicle control or (ii) pretreated with SB202190 for
2 h prior to the addition of PV IgG. A third group of cells was
treatedwith PV IgG and then SB202190 3 h after the addition of
PV IgG. Six hours after the addition of PV IgG, cells were
washed with ice-cold PBS three times and then fixed in 3.7%
paraformaldehyde, permeabilized with 0.5% Triton X-100, and
blocked for 1 h at room temperature with 5% goat serum in PBS
followed by an overnight incubation at 4 °C with mouse anti-
human cytokeratin 5/8 antibodies (BD Biosciences). Samples
were washed three times and probed with Cy3-conjugated sec-
ondary antibodies (Jackson ImmunoResearch Laboratories).
Images were captured with a Leica confocal microscope using
the 63 objective (2 zoom).
Terminal Deoxynucleotidyl Transferase-mediated Biotiny-
latedUTPNick End Labeling (TUNEL) Assay—ATUNEL assay
kit was obtained from R&D Systems (Minneapolis, MN) and
used on skin cryosections and freshly prepared human kerati-
nocytes per the manufacturer’s instructions. Briefly, cell mem-
braneswere permeabilizedwith proteinase K for tissue sections
or with cytonin for cultured cells. Endogenous peroxidase
activity was quenched using 3% H2O2 for 5 min. The biotiny-
lated nucleotides incorporated into the DNA fragments by ter-
minal deoxynucleotidyltransferase were detected using
streptavidin-horseradish peroxidase conjugate followed by the
substrate diaminobenzidine. Sections were counterstained
withMethylGreen. Controls consisted of omitting the terminal
deoxynucleotidyltransferase enzyme form the labeling solution
(negative control) or pretreating the sections for 30 min with
DNase to induce DNA strand breaks (positive control). The
negative control gave no staining, whereas the positive control
stained all nuclei in all layers of the epidermis. TUNEL staining
at different time pointswas quantified by counting theTUNEL-
positive cells in each sample. For each slide, three fields were
randomly chosen using a defined rectangular area (20 objec-
tive) for the average, and the assays were performed in tripli-
cate. Statistical analyses were performed on the data with SPSS
software (version 11.0, SPSS Inc., Chicago, IL). Values were
expressed as mean  S.E. Where indicated, data were com-
pared using the Mann-Whitney U test. Statistical significance
was defined as p  0.05.
In Vivo Inhibitor Studies—For in vivo inhibitor studies, mice
were assigned to each of the following three groups. In groupA,
micewere treatedwith only PF IgGas described above. In group
B, we followed the established split dose protocol (16). Mice
were preinjected with 6.25 g of SB202190 in 50 l intrader-
mally and then reinjected intradermally with 6.25 g of
SB202190 plus PF IgG in 50l (total of 12.5g of SB202190). In
group C, mice were injected intradermally with PF IgG first,
and 4 h later, they received an injection of 12.5 g of SB202190.
All mice received the same dose of PF IgG (0.1 mg/g of body
weight). For immunoblots, signal intensity from the ECL reac-
tion for each band was quantified with a GeneGnomeHR scan-
ner (Syngene) using GeneSnap software (n  3, S.D. shown by
error bars in Fig. 6). The phospho-p38MAPK signal was nor-
malized to total p38MAPK for each sample. Statistical analyses
were performed on the data with SPSS software (version 11.0,
SPSS Inc.). Results from three independent experiments were
expressed as mean  S.D. Where indicated, data were com-
pared using the Student’s t test. Statistical significance was
defined as p  0.05.
RESULTS
Pemphigus IgG Induces Two Peaks of p38MAPKActivation in
Vivo—To examine the relationship of p38MAPK activation to
apoptosis, time course studieswere performed in the PF passive
transfer mouse model. Neonatal C57BL/6J mice were injected
intradermally with PF IgG as described previously (16, 17).
After various time points, mice were examined clinically, and
skin biopsies were obtained for histological, immunological,
and biochemical analyses. Under the conditions used for these
experiments, acantholysis was not observed within the first 8 h
after injection of PF IgG (Fig. 1A). At later time points, blister
formation was readily apparent both clinically and in histologic
sections. Antibodies to phospho-p38MAPK were used to stain
frozen sections from skin biopsies.Within 2–4 h after receiving
PF IgG, increased phospho-p38MAPK activity could be
detected in the epidermis of PF IgG-treated mice by immun-
ofluorescent staining of frozen sections (Fig. 1B). Staining for
phospho-p38MAPK was diminished at 6 h relative to the 4-h
time point but increased again at 8 h and subsequent time
points. To further analyze the in vivo time course of p38MAPK
phosphorylation, extracts from skin biopsies of the above PF
IgG-treated mice were prepared, separated by SDS-PAGE, and
probed by immunoblot for phospho-p38MAPK and total-
p38MAPK activity (Fig. 2). Confirming the results observed by
IF staining, two peaks of phospho-p38MAPK activity were
detected: (i) an early peak at 2–4 h after PF IgG injection and (ii)
a later peak at 8 h and subsequent time points.
FIGURE 1. Phospho-p38MAPK activity is detected in epidermal keratino-
cytes of PF IgG-treated mice at 4, 8, and 21 h but not at 6 h, suggesting
biphasic activation of p38MAPK. Phospho-p38MAPK immunoreactivity is
seen in skin biopsies of mice treated with PF IgG and precedes blistering.
Neonatal C57BL/6J mice were injected intradermally with PF IgG for the indi-
cated times. A, skin biopsies examined by routine hematoxylin and eosin
(20). Blister formation is not seen within the first 8 h after injection of PF IgG
but is readily apparent at 21 h; the intraepithelial cleavage plane is marked by
the black arrow. B, antibodies to phospho-p38MAPK were used to stain frozen
sections of skin biopsies of mice treated with PF IgG for the indicated times
and examined by confocal immunofluorescence microscopy. A PBS-treated
control (CON) is shown for comparison. Immunofluorescent staining for
phospho-p38MAPK is apparent in biopsies of mice treated with PF IgG for 4 h,
markedly diminished at 6 h, but increased again at 8 and 21 h. The asterisk
marks the stratum corneum; the white arrow marks the epidermal keratino-
cytes magnified in the inset.
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Pemphigus IgG Induces Two Peaks of p38MAPKActivation in
Keratinocyte Monolayer Cultures—Pemphigus passive transfer
mice more closely model in vivo biology when compared with
tissue culture systems; however, it can be difficult to control for
rates of absorption of PF IgG among the test animals. To ensure
that the biphasic nature of p38MAPK activity was not due to
variability in PF IgG absorption rates among the test animals,
wenext examined the time course of phospho-p38MAPKactiv-
ity in primary human keratinocyte cultures. Dsg3, not dsg1, is
the predominant desmosomal desmoglein in primary human
keratinocyte monolayer cultures; therefore, purified PV IgG
was used for the tissue culture experiments. Normal human
keratinocytes were incubated with PV IgG for various times
from 0 to 10 h; extracts were prepared, separated by SDS-
PAGE, and probed by immunoblot for phospho-p38MAPKand
total p38MAPK. Similar to the above in vivo experiments, two
peaks of phospho-p38MAPK activity were observed in normal
human keratinocytes treated with PV IgG (Fig. 3): (i) an early
peak observed within 30 min of the addition of PV IgG to cul-
tures and (ii) a second later peak seen at 6–10 h after the addi-
tion of PV IgG.
Apoptosis Is a Late Event, Occurring after the Second Peak of
p38MAPK Activity—Next, both PF IgG-treated mice and PV
IgG-treated keratinocyte cultures were examined for markers
of apoptotic activity. Extracts prepared from skin biopsies of PF
IgG-treated mice were separated by SDS-PAGE and probed by
immunoblot for two markers of apoptotic activity, cleaved
FIGURE 2. Time course of p38MAPK activation in mice treated with PF IgG.
Two peaks of phospho-p38MAPK (P-P38MAPK) activity are detected by West-
ern blot of skin extracts from PF IgG-treated mice. The first peak of p38MAPK
activity is observed at 4 h, and the second peak is observed at 8 –21 h. Neo-
natal C57BL/6J mice were injected intradermally with PF IgG (0.1 mg/g of
body weight) or control (Con) IgG for the indicated times. A, Western blots of
three independent time course experiments. Extracts (20 g of protein/lane)
from skin biopsies of mice were separated by SDS-PAGE, transferred to poly-
vinylidene difluoride, and immunoblotted with antibodies to phospho-
p38MAPK and total p38MAPK. B, signal intensity from the ECL reaction for
each band was quantified with a GeneGnome HR scanner and GeneSnap
software. Each time course (TC) was individually plotted. Biphasic activation
of p38MAPK was induced by PF IgG in vivo.
FIGURE 3. Time course of p38MAPK phosphorylation in cultured normal
human keratinocytes treated with PV IgG. Normal human keratinocytes
cultured to 80 –90% confluence were treated with PV IgG (3.0 mg/ml) for the
indicated times, and extracts (15 g of protein/lane) were separated by 10%
SDS-PAGE. Blots were probed with antibodies to phospho-p38MAPK
(P-P38MAPK), stripped, and then reprobed with antibodies to p38MAPK. Sim-
ilar to the in vivo experiments with PF IgG, biphasic activation of p38MAPK is
observed in keratinocytes treated with PV IgG.
FIGURE 4. Increased apoptotic activity is observed subsequent to activa-
tion of p38MAPK in PF passive transfer mice. Neonatal C57BL/6J mice
were injected intradermally with PF IgG for various times from 1 to 48 h, and
skin biopsies were obtained for biochemical analysis and for TUNEL. A, immu-
noblots of murine skin biopsy extracts (50 g/lane) using antibodies to
cleaved PARP and cleaved caspase 3, two markers of apoptosis. B, marked
increases in TUNEL-positive keratinocytes were not observed until mice were
treated with PF IgG for periods exceeding 21 h. Controls consisted of omitting
the terminal deoxynucleotidyltransferase enzyme from the labeling solution
(negative control (Negative)) or pretreating sections for 30 min with DNase to
induce DNA strand breaks (positive control (Positive)).
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PARP and cleaved caspase 3. Cleaved PARP and cleaved
caspase 3were not detected at 0–24 h after PF IgG injection but
were readily detected at the late time points of 30 and 48 h (Fig.
4A). As an additional probe for apoptosis, skin biopsies fromPF
IgG-treated mice were subjected to TUNEL staining (Fig. 4B).
TUNEL staining was not detected at early time points in vivo
but could be detected at later time points in biopsies where
acantholysis was already present.
Next, cleaved nuclear PARP and TUNEL staining were used
to examine the temporal relationship of p38MAPK phospho-
rylation to apoptotic activity in PV IgG-treated normal human
keratinocyte cultures (Fig. 5). Normal human keratinocyte cul-
tures were treated with control IgG or pathogenic PV IgG or
mock-incubated with buffer for var-
ious times from 0 to 10 h. Cells were
fixed and stained with amonoclonal
antibody that recognizes cleaved
PARP (Fig. 5A). No cleaved PARP
was detected in cells treated for 10 h
with either buffer or control IgG. In
contrast, time-dependent detection
of cleaved PARP was observed in
cells treated with PV IgG. No
cleaved PARP was detected in cells
treated with PV IgG for 1 h. A signal
for cleaved PARP became detecta-
ble in cells treated with PV IgG for
6 h but wasmore readily apparent at
10 h. Similar results were observed
when cultures were examined by
TUNEL stain (Fig. 5, B and C). Sim-
ilar numbers of TUNEL-positive
cells were observed in keratinocytes
treated with control or PV IgG for 1
and 6 h. After 10 h, PV IgG-treated
cells demonstrated more TUNEL-
positive cells (five per high powered
field) when compared with control
IgG-treated cells (two per high pow-
ered field), although the number of
TUNEL-positive cells observed
after 10 h exposure to PV IgG was
still relatively small.
Inhibition of the First, butNot Sec-
ond, Peak of p38MAPK Activation
Blocks Blistering in Vivo—Inhibitor
studies were performed next to
determine the association of each
peak of p38MAPK activity with
blister formation. Inhibition of the
first peak of p38MAPK activation
blocked blistering, whereas inhibi-
tion of the later second peak of
p38MAPK activation failed to block
blistering in vivo (Fig. 6 and Table
1). Neonatal mice were divided into
three groups. The first group
received PF IgG alone. The second
group was pretreated with the p38MAPK inhibitor SB202190
before injection with PF IgG to block both the first and the
second peaks of p38MAPK activation. The third group initially
received PF IgG, and then 4 h later, was treated with SB202190
to block the second, but not the first, peak of p38MAPKactivity.
Mice injected with PF IgG alone developed blisters (Fig. 6A);
using phospho-p38MAPK-specific antibodies, direct immuno-
fluorescence of skin biopsies (Fig. 6B) and immunoblot of skin
biopsy extracts (Fig. 6C) demonstrated phospho-p38MAPK
activity in the epidermis of PF IgG-treated mice. Consistent
with previous reports, PF IgG-induced p38MAPK phosphoryl-
ation and blister formation were blocked in mice pretreated
with the p38MAPK inhibitor SB202190. In contrast, blister for-
FIGURE 5. Detection of apoptosis in PV-IgG-treated normal human keratinocyte. Normal human keratino-
cytes were grown to 80 –90% confluence and exposed to control IgG or PV IgG (3 mg/ml) for the indicated
times. A, treated cells were analyzed for the presence of cleaved-PARP, a marker of ongoing apoptosis, by
immunofluorescence microscopy. Actin filaments were labeled with Alexa Fluor 488-conjugated phalloidin
(green), and nuclei were stained with 4,6-diamidino-2-phenylindole (blue). B, TUNEL showed an increase in
TUNEL-positive cells when cells were incubated with PV IgG for 10 h, but not at 1 or 6 h, when compared with
control IgG-treated cells. Controls for TUNEL staining consisted of omitting the terminal deoxynucleotidyl-
transferase enzyme form the labeling solution (negative control (Negative)) or pretreating sections for 30 min
with DNase to induce DNA strand breaks (positive control (Positive)). C, TUNEL staining at different time points
was quantified by counting the TUNEL-positive cells in each sample. For each slide, three fields were randomly
chosen using a defined rectangular area (20 objective); assays were performed in triplicate. S.D. is shown by
error bars; the asterisk indicates p  0.046 for comparison of control and PV IgG-treated cells at the 10-h time
point. p values were determined using the Mann-Whitney U test.
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mation was not blocked in the group of mice first treated with
PF IgG and 4 h later treated with SB202190. In this last group of
mice, the addition of the inhibitor 4 h after PF IgG blocked
subsequent p38MAPK activation as evidenced by themarkedly
diminished phospho-p38MAPK signal on IF (Fig. 6A) and
immunoblot (Fig. 6, B and C). In addition to blocking the sec-
ond peak of p38MAPKactivation, in vivo activation of caspase 3
was also blocked in mice that received the p38MAPK inhibitor
4 h after injection of PF IgG (Fig. 6D).
Inhibition of the First, but Not Second, Peak of p38MAPK
Activation Blocks PV IgG-triggered Cytokeratin Retraction—
Previously, we had shown that p38MAPK inhibition blocked
the ability of PV IgG to induce cytoskeletal reorganization (15).
Therefore, inhibitor studies were
next performed to determine the
association of each peak of
p38MAPK activity with cytokeratin
retraction. If p38MAPK-dependent
cytokeratin retraction was linked to
pemphigus IgG-induced loss of
adhesion, then inhibition of the
first, but not second, peak of
p38MAPK activation would be
expected to block pemphigus IgG-
induced cytokeratin retraction. To
test this, primary human keratino-
cytes were (i) treated with PV IgG
alone (Fig. 7B), (ii) pretreated with
the p38MAPK inhibitor SB202190
2 h prior to the addition of PV IgG to
block both the first and the second
peaks of p38MAPK activation (Fig.
7C), or (iii) treated with SB202190
3 h after PV IgG treatment to block
the second, but not the first, peak of
p38MAPK activity (Fig. 7D). At var-
ious times after the addition of PV
IgG, cells were fixed and stained for
cytokeratin 5/8 and examined by
confocal microscopy. Increased
cytokeratin retraction is observed
over time in keratinocytes treated
with PV IgG. In cells pretreatedwith
the p38MAPK inhibitor (prior to
the first peak), cytokeratin retrac-
tion is blocked. In contrast, treating
keratinocytes with the p38MAPK
inhibitor after the first peak of
p38MAPK activity, but prior to the
second peak, failed to block PV IgG-
triggered cytokeratin retraction.
DISCUSSION
In previous studies, both in tissue
culture and in vivo, we have demon-
strated that both pathogenic PV and
PF IgG induced blistering via
p38MAPK-dependent signaling
within the target keratinocytes (15–18). The activation of
p38MAPK by pemphigus IgG has been confirmed by other
investigators (10, 37). p38MAPK is a ubiquitous kinase that is
involved in a variety of cellular processes, including regulation
of the cytoskeleton, stress response signaling, and activation of
apoptotic pathways. In our previous work (15), we had demon-
strated that activation of p38MAPK was a rapid response,
occurring within 30 min of the addition of PV IgG to normal
human keratinocyte cultures. In these cultures, activation of
p38MAPK preceded changes in the cytoskeleton and loss of
cell-cell adhesion. Notably, pretreating keratinocyte cultures
with p38MAPK inhibitors blocked PV IgG-induced keratin
intermediate filament collapse and actin reorganization (15).
FIGURE 6. Inhibition of the first peak of p38MAPK activity blocked blister formation, whereas inhibition
of the second peak failed to block blistering in vivo. Neonatal mice (n  3 per treatment group) were
injected intradermally with 1) PF IgG only, 2) the p38MAPK inhibitor SB202190 2 h before PF IgG injection, or 3)
the p38MAPK inhibitor SB202190 4 h after PF IgG injection. After 18 h, the skin of the three different groups was
examined. A, skin biopsies examined by routine hematoxylin and eosin (H&E, 20) and by direct immunoflu-
orescence (IF) using phospho-p38MAPK (P-P38MAPK) antibodies. Blistering is observed in PF IgG-treated mice
but not in inhibitor-pretreated mice. In contrast, blistering is observed when the inhibitor is administered 4 h
after PF IgG. The arrow shows increased phospho-p38MAPK IF signal in PF IgG-treated mice. B, extracts from
skin biopsies of three mice (lanes 1–3) from each treatment group were probed by immunoblot with antibodies
to phospho-p38MAPK and total p38MAPK. C, signal intensity from the ECL reaction for each band was quan-
tified with a GeneGnome HR scanner (Syngene) using GeneSnap software (n  3, S.D. shown by error bars). The
phospho-p38MAPK signal was normalized to total p38MAPK for each sample. p values (*, p  0.001; **, p 
0.001) were calculated using the Student’s t test. D, neonatal mice were treated with 1) control (Con) IgG, 2) PF
IgG, or 3) the p38MAPK inhibitor SB202190 4 h after PF IgG injection to block the second peak of p38MAPK
activation. After 30 h, extracts from skin biopsies were probed with antibodies to phospho-p38MAPK, total
p38MAPK, or cleaved caspase 3. In the mice treated with the inhibitor 4 h after PF IgG, the second peak of
p38MAPK activity and the increase in caspase 3 cleavage are blocked.
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Furthermore, in both PV and PF passive transfer mouse mod-
els, (i) p38MAPK and HSP 25 phosphorylation were observed
in the skin and (ii) pretreating mice with p38MAPK inhibitors
blocked blister induction by PV (16) and PF IgG (17).
In the present investigation, we have extended our studies on
p38MAPK signaling using both the passive transfer PF mouse
model and the in vitro PV keratinocyte culture system. In pri-
mary human keratinocytes, dsg3 is the predominant desmo-
somal cadherin; therefore, PV IgG was utilized to examine the
time course of p38MAPK activation in primary human kerati-
nocyte tissue culture. In vivo time course studies require large
amounts of a single pathogenic IgG. To undertake the studies,
we utilized a PF IgG, which was available to us in sufficiently
large quantities to perform the necessary studies. We found
that inmice, PF IgG triggers a biphasic activation of p38MAPK,
producing an early peak at 2–4 h of the intradermal injection of
the pathogenic autoantibody. The second peak appears at 8 h,
and it is sustained until 30 h after IgG injection. Similarly, PV
IgG in the cell culture system also induces a biphasic activation
of p38MAPK, with the first activation at 30min to 2.5 h and the
second activation after 6 h of the introduction of the pathogenic
autoantibody.
The temporal relationship of the first and second peaks of
p38MAPK activation to blistering was tested in vivo and in
vitro. By timing the administration of the inhibitor, either both
peaks or the second peak of p38MAPK activation could be
selectively blocked. It is likely that the first peak triggers a series
of intracellular events that leads to acantholysis because admin-
istration of a p38MAPK inhibitor prior to the injection of IgG
blocked acantholysis and disease in mice and PV IgG-induced
cytokeratin retraction in keratinocyte cultures, whereas admin-
istration of the inhibitor to selectively block the second peak of
p38MAPK phosphorylation failed to block acantholysis in vivo
and cytokeratin retraction in vitro (Fig. 8).
In prior studies, we had demon-
strated that PV IgG-induced acan-
tholysis is mediated by activation of
p38MAPK with subsequent phos-
phorylation of HSP27, actin reorga-
nization, and cytokeratin retraction.
Both p38MAPK and HSP27 regu-
late actin and intermediate filaments
(19–25), suggesting a mechanistic
role for p38MAPK and HSP27 in
pemphigus-induced cytoskeletal
alterations and acantholysis. In this
current study, we have extended
these initial observations to demon-
strate two peaks of p38MAPK phos-
phorylation in response to pemphi-
gus IgG. We interpret the data to
indicate that the first peak of
p38MAPK is part of the mechanism
by which pemphigus IgG induces
acantholysis, whereas the second
peak of p38MAPK activation is not
required for cytoskeletal reorganiza-
tion nor blistering.
FIGURE 7. Inhibition of the first peak of p38MAPK activity blocked PV
IgG-triggered cytokeratin retraction, whereas inhibition of the second
peak did not. Primary human keratinocytes were treated with (A) vehicle
(DMSO) control, (B) vehicle control 2 h prior to PV IgG, (C) SB202190 2 h prior
to PV IgG treatment, or (D) SB202190 3 h after PV IgG treatment. Six hours
after the addition of PV IgG, cells were fixed and stained for cytokeratin 5/8
and examined by confocal microscopy. Increased cytokeratin retraction is
observed over time in keratinocytes treated with PV IgG (B). In cells pretreated
with the p38MAPK inhibitor (prior to the first peak), cytokeratin retraction is
blocked. In contrast, treating keratinocytes with the p38MAPK inhibitor after
the first peak of p38 activity, but prior to the second peak, failed to block PV
IgG-triggered cytokeratin retraction (D).
FIGURE 8. Model for the temporal relationship of pemphigus IgG-mediated activation of p38MAPK to
blistering and apoptosis. Two peaks of p38MAPK phosphorylation occur subsequent to treatment with
pemphigus IgG. Inhibiting the first, but not second, peak of p38MAPK activity blocks blistering. Markers of
apoptosis, including caspase 3 cleavage, PARP cleavage, and TUNEL-positive staining, occur subsequent to the
second peak of p38MAPK phosphorylation. Blocking the first peak of p38MAPK phosphorylation blocks blis-
tering, indicating a role for the first peak of p38MAPK activation in loss of cell-cell adhesion. In contrast,
blocking this second peak of p38MAPK phosphorylation fails to block blistering but blocks increases in apo-
ptotic markers (e.g. caspase 3 cleavage). The second peak of p38MAPK phosphorylation is not part of the
mechanism of acantholysis but may represent stress response signaling secondary to acantholysis.
TABLE 1
Inhibition of histological disease
A total of 50 mice were injected. The p38MAPK inhibitor SB202190 blocks blister-






PF IgG (n  17) 17 0
p38 inhibitor (SB202190)
2 h before PF IgG (n  16)
1 15
p38 inhibitor (SB202190)
4 h after PF IgG (n  17)
16 1
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One of the potential mechanisms that could be set in motion
following p38MAPKactivation is the induction of proapoptotic
pathways. A number of investigators have observed the induc-
tion of keratinocyte apoptosis by PV IgG in tissue culture (32–
34) or in skin biopsy specimens from PV or PF patients (31), (i)
raising the possibility that apoptosis is part of themechanismby
which pemphigus IgG induces blistering and (ii) implicating a
role for p38MAPK in the induction of apoptosis. In the time
course studies in the PV tissue culture model, markers of apo-
ptosis including PARP cleavage and TUNEL stain were not
observed at 1 h but became detectable at 6 h and more readily
detectable at 10 h, correlating with the appearance of the sec-
ond peak of p38MAPK activation. In the mouse model of PF,
TUNEL staining is negative at 2 and 6 h after IgG injection but
became apparent at 21 h when disease developed. However,
cleaved PARP and caspase 3 were not detected until 30 h after
IgG injection. Althoughwe cannot completely rule out the pos-
sibility that the failure to detect the cleaved PARP or caspase 3
byWestern blot at the earlier time points before 30 hwas due to
the sensitivity of the technique used, these data suggest that
apoptosis occurs simultaneously or subsequently to the second
peak of p38MAPK activity and acantholysis. Importantly, inhi-
bition of the second peak of p38MAPK activation also blocked
caspase 3 cleavage, suggesting that activation of this proapopto-
tic proteinase was dependent upon the second peak of
p38MAPK activity.
Althoughour data suggest that the activation of proapoptotic
pathways is a late event andmaynot be essential for blistering in
pemphigus, the data do not exclude the possibility that activa-
tion of components of apoptotic signaling, including caspase
family member proteinases, could augment the blistering
response as downstream effects of p38MAPK activation. This
hypothesis is supported by the observation that caspase inhib-
itors block pemphigus IgG-induced acantholysis in the passive
transfer mouse model.3 The potential for caspase-dependent
proteolysis to augment the pathogenic response in pemphigus
is supported by the observation that components of the desmo-
some including dsg3, dsg1, plakoglobin, and desmoplakin (38,
39), as well as intermediate filaments (40, 41), have all been
shown toundergo caspase-dependent cleavage. InA431 epithe-
lial cells induced to undergo apoptosis byUV exposure, caspase
3-dependent and matrix metalloproteinase (MMP)-dependent
cleavage of dsg1 has been observed (39). In this system, caspase
3 cleavage occurredwithin the cytoplasmic tail of dsg1, whereas
MMP-dependent cleavage resulted in shedding of a 75-kDa
fragment of the dsg1 ectodomain. Interestingly, UV-induced
MMP cleavage of the dsg1 ectodomain was not only inhibited
by the MMP inhibitor TAPI-0 but also by the caspase inhibitor
ZVAD-fmk (39). In addition, the pathophysiology of staphylo-
coccal scalded skin syndrome demonstrates that proteolysis of
desmosome components can contribute to destabilization of
desmosomes (42). Direct proteolysis of the dsg1 ectodomain
induces loss of cell-cell adhesion in staphylococcal scalded skin
syndrome, which, like PF, is characterized histologically by sub-
corneal blister formation. In staphylococcal scalded skin syn-
drome, subcorneal blistering results from cleavage of the dsg1
ectodomain by Staphylococcus aureus exfoliative toxin A, a ser-
ine proteinase (43). Thus, blocking caspase-dependent dsg deg-
radation may augment cell-cell adhesion and decrease kerati-
nocyte sensitivity to the acantholytic effects of pathogenic
pemphigus IgG.
The presence or absence of adhesion represents a major bio-
logic shift requiring coordination among various biological
processes, including those regulating adhesion, migration, pro-
liferation, differentiation, and cell death. For example, contact
inhibition, in which proliferation is suppressed as cells contact
and form adhesive interactionswith one another, demonstrates
the association between adhesion and proliferation. It is likely
that changes in desmosome adhesion and signaling initiated by
pemphigus IgG contribute to the regulation of these biological
transitions.Whether a cell differentiates,migrates, proliferates,
or dies when desmosome adhesion is disrupted is likely to be
context-dependent; that is, additional non-desmosome-medi-
ated signaling processes are likely to influence which of these
fates ensues. Although we are beginning to identify molecular
components of the mechanism by which pemphigus autoanti-
bodies induce loss of cell-cell adhesion, the biology of acanthol-
ysis is likely to be complex. More work will need to be done to
develop an integrated understanding of these transitions.
Clearly, the ability of pemphigus IgG to induce changes in cell-
cell adhesion in vitro and in vivo provides not only a useful
reagent to initiate adhesive transitions at the desmosome but
also a physiologically relevant human disease-specific model
system in which to further probe the molecular mechanism by
which these processes proceed.
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